261 related articles for article (PubMed ID: 18785547)
21. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
[TBL] [Abstract][Full Text] [Related]
22. [Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].
Hidalgo M; Reyes J; Cárdenas AM; Díaz L; Rincón S; Vanegas N; Díaz PL; Castañeda E; Arias CA
Biomedica; 2008 Jun; 28(2):284-94. PubMed ID: 18719726
[TBL] [Abstract][Full Text] [Related]
23. Comparison of in vitro susceptibilities of ocular bacterial isolates to gatifloxacin and other topical antibiotics.
Kaliamurthy J; Nelson Jesudasan CA; Geraldine P; Parmar P; Kalavathy CM; Thomas PA
Ophthalmic Res; 2005; 37(3):117-22. PubMed ID: 15746568
[TBL] [Abstract][Full Text] [Related]
24. [Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
Loza E; Cantón R; Pascual A; Tubau F; Morosini MI; Almaraz F; Perea E; Martín R; Jones RN; Baquero F
Enferm Infecc Microbiol Clin; 2003 Oct; 21(8):404-9. PubMed ID: 14525705
[TBL] [Abstract][Full Text] [Related]
25. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network.
Karlowsky JA; Kelly LJ; Thornsberry C; Jones ME; Evangelista AT; Critchley IA; Sahm DF
Int J Antimicrob Agents; 2002 Jan; 19(1):21-31. PubMed ID: 11814764
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
Hansen GT; Blondeau JM
J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
[TBL] [Abstract][Full Text] [Related]
27. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates.
Miller D; Flynn PM; Scott IU; Alfonso EC; Flynn HW
Arch Ophthalmol; 2006 Apr; 124(4):479-83. PubMed ID: 16606872
[TBL] [Abstract][Full Text] [Related]
28. Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.
Bosso JA; Mauldin PD
Antimicrob Agents Chemother; 2006 Jun; 50(6):2106-12. PubMed ID: 16723572
[TBL] [Abstract][Full Text] [Related]
29. Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000.
White RL; Enzweiler KA; Friedrich LV; Wagner D; Hoban D; Bosso JA
Diagn Microbiol Infect Dis; 2002 Jul; 43(3):207-17. PubMed ID: 12106954
[TBL] [Abstract][Full Text] [Related]
30. [Comparative research of the efficacy of the gatifloxacin and levofloxacin for bacterial conjunctivitis in human eyes].
Gong L; Sun XH; Qiu XD; Zhang YQ; Qu J; Yuan ZL; Xiong QC
Zhonghua Yan Ke Za Zhi; 2010 Jun; 46(6):525-31. PubMed ID: 21055198
[TBL] [Abstract][Full Text] [Related]
31. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones.
Hwang DG
Surv Ophthalmol; 2004 Mar; 49 Suppl 2():S79-83. PubMed ID: 15028483
[TBL] [Abstract][Full Text] [Related]
32. Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002.
Morrissey I; Burnett R; Viljoen L; Robbins M
J Infect; 2004 Aug; 49(2):109-14. PubMed ID: 15236917
[TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Moczygemba LR; Frei CR; Burgess DS
Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
[TBL] [Abstract][Full Text] [Related]
34. Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections.
Epstein SP; Bottone EJ; Asbell PA
Eye Contact Lens; 2006 Sep; 32(5):240-4. PubMed ID: 16974157
[TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa.
Garrison MW
Diagn Microbiol Infect Dis; 2006 Jan; 54(1):51-6. PubMed ID: 16368475
[TBL] [Abstract][Full Text] [Related]
36. [Antibiotic susceptibility patterns of bacteria isolated from keratitis and intraocular infections at Fundación Oftalmológica de Santander (FOSCAL), Floridablanca, Colombia].
Galvis V; Tello A; Guerra A; Acuña MF; Villarreal D
Biomedica; 2014 Apr; 34 Suppl 1():23-33. PubMed ID: 24968033
[TBL] [Abstract][Full Text] [Related]
37. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data.
Kowalski RP; Yates KA; Romanowski EG; Karenchak LM; Mah FS; Gordon YJ
Ophthalmology; 2005 Nov; 112(11):1987. PubMed ID: 16183128
[TBL] [Abstract][Full Text] [Related]
38. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.
Dholakia N; Rolston KV; Ho DH; LeBlanc B; Bodey GP
Antimicrob Agents Chemother; 1994 Apr; 38(4):848-52. PubMed ID: 8031057
[TBL] [Abstract][Full Text] [Related]
39. Aqueous penetration of gatifloxacin and levofloxacin into the rabbit aqueous humor following topical dosing.
Levine JM; Noecker RJ; Lane LC; Snyder RW; Rapedius M; Blanchard J
J Ocul Pharmacol Ther; 2004 Jun; 20(3):210-6. PubMed ID: 15279726
[TBL] [Abstract][Full Text] [Related]
40. [In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
Noviello S; Ianniello F; Leone S; Esposito S
Infez Med; 2006 Mar; 14(1):24-8. PubMed ID: 17405239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
